Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Chronic Heart Failure

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 214 articles: HTML format Text format

Single Articles

June 2018
1. LAM CSP, Voors AA, de Boer RA, Solomon SD, et al
   Heart failure with preserved ejection fraction: from mechanisms to therapies.
   Eur Heart J. 2018 Jun 13. pii: 5037246. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   May 2018
2. LUSCHER TF
   Mechanisms and outcomes of heart failure: from HFpEF, HFmrEF, and HFrEF to transplantation.
   Eur Heart J. 2018;39:1749-1753.
   PubMed     Text format    
   
   
   
3. ANGERMANN CE, Frantz S, Maack C
   The Comprehensive Heart Failure Centre in Wurzburg, Germany.
   Eur Heart J. 2018;39:1757-1760.
   PubMed     Text format    
   
   
   
4. SWOBODA PP, Plein S
   Heart failure in Diabetic patients.
   Eur Heart J. 2018;39:1755-1757.
   PubMed     Text format    
   
   
   
5. OBOKATA M, Olson TP, Reddy YNV, Melenovsky V, et al
   Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.
   Eur Heart J. 2018 May 19. pii: 4999864. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   March 2018
6. VADUGANATHAN M, Solomon SD
   Expanding the global borders of heart failure: the SHOP and PEOPLE studies.
   Eur Heart J. 2018 Mar 22. pii: 4951580. doi: 10.1093.
   PubMed     Text format    
   
   
   
7. FONSECA C
   A Heart Failure Clinic.
   Eur Heart J. 2018;39:826-828.
   PubMed     Text format    
   
   
   
8. BEGGS S, Gardner R
   Thirty years of heart failure.
   Eur Heart J. 2018;39:824-826.
   PubMed     Text format    
   
   
   February 2018
9. EL HARANE N, Kervadec A, Bellamy V, Pidial L, et al
   Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.
   Eur Heart J. 2018 Feb 6. pii: 4840711. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   January 2018
10. LAM CSP, Gamble GD, Ling LH, Sim D, et al
    Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
    Eur Heart J. 2018 Jan 29. pii: 4829677. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
11. NELSON MD, Wei J, Bairey Merz CN
    Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?
    Eur Heart J. 2018 Jan 16. pii: 4811982. doi: 10.1093.
    PubMed     Text format    
    
    
    
12. HEINZMANN D, Seizer P
    Mitochondria in heart failure: EMID-sign.
    Eur Heart J. 2018 Jan 3. pii: 4786075. doi: 10.1093.
    PubMed     Text format    
    
    
    
13. LUND LH, Kober L, Swedberg K, Ruschitzka F, et al
    The year in cardiology 2017: heart failure.
    Eur Heart J. 2018 Jan 2. pii: 4774532. doi: 10.1093.
    PubMed     Text format    
    
    
    
14. LUSCHER TF
    Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation.
    Eur Heart J. 2018;39:1-4.
    PubMed     Text format    
    
    
    
15. PACKER M
    The Future Treatment of Heart Failure?
    Eur Heart J. 2018;39:5-7.
    PubMed     Text format    
    
    
    December 2017
16. TAQUETI VR, Solomon SD, Shah AM, Desai AS, et al
    Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.
    Eur Heart J. 2017 Dec 26. pii: 4775060. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
17. ARRIGO M, Vodovar N, Nougue H, Sadoune M, et al
    The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
    Eur Heart J. 2017 Dec 13. pii: 4735305. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
18. WILCOX JE, Mann DL
    Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?
    Eur Heart J. 2017 Dec 11. pii: 4728646. doi: 10.1093.
    PubMed     Text format    
    
    
    November 2017
19. MASIP J, Peacock WF, Price S, Cullen L, et al
    Indications and practical approach to non-invasive ventilation in acute heart failure.
    Eur Heart J. 2017 Nov 26. pii: 4654494. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
20. GRASSI G, Mancia G
    'Keep an eye' on the heart: retinal microcirculation disarray in congestive heart failure.
    Eur Heart J. 2017 Nov 23. pii: 4654727. doi: 10.1093.
    PubMed     Text format    
    
    
    
21. NICHOLLS M
    Finn Waagstein MD PhD: Finn Waagstein reflects on his work and research which saw beta-blockers revolutionise the treatment of heart failure patients. Mark Nicholls reports.
    Eur Heart J. 2017;38:3249-3250.
    PubMed     Text format    
    
    
    
22. ROSANO GMC
    HFA Congress 2017: The Congress of the Heart Failure Association of the ESC: a continuous success story, the result of a long-term vision.
    Eur Heart J. 2017;38:3042-3043.
    PubMed     Text format    
    
    
    
23. TOFIELD A
    Heart Failure Congress sets record: The 2017 ESC Heart Failure Association Congress had a new record number of submissions for original science.
    Eur Heart J. 2017;38:3041.
    PubMed     Text format    
    
    
    October 2017
24. NAGELE MP, Barthelmes J, Ludovici V, Cantatore S, et al
    Retinal microvascular dysfunction in heart failure.
    Eur Heart J. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
25. CLELAND JGF, Bunting KV, Flather MD, Altman DG, et al
    Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
    Eur Heart J. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
26. LUSCHER TF
    Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles.
    Eur Heart J. 2017;38:2857-2859.
    PubMed     Text format    
    
    
    
27. BLANTON RM
    What can haemodynamic profiles teach us about heart failure in the paediatric population?
    Eur Heart J. 2017;38:2910-2911.
    PubMed     Text format    
    
    
    
28. PITT B, Rossignol P
    Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?
    Eur Heart J. 2017;38:2897-2899.
    PubMed     Text format    
    
    
    
29. CHEN S, Dykes JC, McElhinney DB, Gajarski RJ, et al
    Haemodynamic profiles of children with end-stage heart failure.
    Eur Heart J. 2017;38:2900-2909.
    PubMed     Text format     Abstract available
    
    
    
30. ALDAHL M, Jensen AC, Davidsen L, Eriksen MA, et al
    Associations of serum potassium levels with mortality in chronic heart failure patients.
    Eur Heart J. 2017;38:2890-2896.
    PubMed     Text format     Abstract available
    
    
    August 2017
31. FITCHETT D, Butler J, van de Borne P, Zinman B, et al
    Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial.
    Eur Heart J. 2017 Aug 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
32. LUSCHER TF
    Update on heart failure: biomarkers, intensive therapy, remote monitoring, and cardiomyocyte renewal.
    Eur Heart J. 2017;38:2315-2317.
    PubMed     Text format    
    
    
    
33. DE BOER RA, Meems LMG, van Veldhuisen DJ
    Vitamin D supplementation in heart failure: case closed?
    Eur Heart J. 2017;38:2287-2289.
    PubMed     Text format    
    
    
    July 2017
34. GOLIASCH G, Bartko PE, Pavo N, Neuhold S, et al
    Refining the prognostic impact of functional mitral regurgitation in chronic heart failure.
    Eur Heart J. 2017 Jul 25. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    June 2017
35. LUSCHER TF
    Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition.
    Eur Heart J. 2017;38:1857-1860.
    PubMed     Text format    
    
    
    
36. ROURA S, Galvez-Monton C, Lupon J, Bayes-Genis A, et al
    Biotherapies and biomarkers for cardiovascular diseases: A 15-year journey at the ICREC (Heart Failure and Cardiac Regeneration) Research Laboratory in Barcelona, Spain.
    Eur Heart J. 2017;38:1784-1786.
    PubMed     Text format    
    
    
    
37. CHATTERJEE NA, Singh JP
    Making sense of remote monitoring studies in heart failure.
    Eur Heart J. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format    
    
    
    
38. SUGIHARA S, Burnett JC Jr
    BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?
    Eur Heart J. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format    
    
    
    May 2017
39. MORGAN JM, Kitt S, Gill J, McComb JM, et al
    Remote management of heart failure using implantable electronic devices.
    Eur Heart J. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
40. SCUFFHAM PA, Ball J, Horowitz JD, Wong C, et al
    Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.
    Eur Heart J. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
41. ZITTERMANN A, Ernst JB, Prokop S, Fuchs U, et al
    Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.
    Eur Heart J. 2017 May 12. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
42. SCHUPKE S, Mehilli J
    Less myocardial scar but greater propensity for heart failure: another gender paradox in myocardial infarction.
    Eur Heart J. 2017 May 5. doi: 10.1093.
    PubMed     Text format    
    
    
    April 2017
43. PANG PS, Butler J, Collins SP, Cotter G, et al
    Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).
    Eur Heart J. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
44. BORLAUG BA, Obokata M
    Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.
    Eur Heart J. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format    
    
    
    
45. LUSCHER TF
    From systemic and pulmonary hypertension to heart failure: novel drugs and devices.
    Eur Heart J. 2017;38:1087-1090.
    PubMed     Text format    
    
    
    
46. CLELAND JGF, Mueller C
    What can we learn from SOCRATES: more questions than answers?
    Eur Heart J. 2017;38:1128-1131.
    PubMed     Text format    
    
    
    
47. MCDIARMID AK, Pellicori P, Cleland JG, Plein S, et al
    Taxonomy of segmental myocardial systolic dysfunction.
    Eur Heart J. 2017;38:942-954.
    PubMed     Text format     Abstract available
    
    
    March 2017
48. PIESKE B, Maggioni AP, Lam CS, Pieske-Kraigher E, et al
    Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Eur Heart J. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
49. MCCULLOUGH PA, Rios A, Smith B
    Dialysis fistulas and heart failure.
    Eur Heart J. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format    
    
    
    
50. OUWERKERK W, Voors AA, Anker SD, Cleland JG, et al
    Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
    Eur Heart J. 2017 Mar 11. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
51. LUSCHER TF
    Frontiers in heart failure: sodium, longitudinal strain, contractility sensor, fatal arrhythmias, and stroke.
    Eur Heart J. 2017;38:693-696.
    PubMed     Text format    
    
    
    
52. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available
    
    
    
53. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
    Eur Heart J. 2017;38:720-726.
    PubMed     Text format     Abstract available
    
    
    February 2017
54. 
    Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction [Eur Heart J 2017; doi:10.1093/eurheartj/ehx014].
    Eur Heart J. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format    
    
    
    
55. MULLENS W, Verbrugge FH, Nijst P, Tang WH, et al
    Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.
    Eur Heart J. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
56. MATHUR A, Fernandez-Aviles F, Dimmeler S, Hauskeller C, et al
    The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    
    
    
    
57. BAYES-GENIS A, Voors AA, Zannad F, Januzzi JL, et al
    Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    
    
    
    
58. BOHM M, Young R, Jhund PS, Solomon SD, et al
    Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Eur Heart J. 2017 Feb 1. doi: 10.1093.
    PubMed     Text format    
    
    
    
59. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
    Agents with vasodilator properties in acute heart failure.
    Eur Heart J. 2017;38:317-325.
    PubMed     Text format    
    
    
    
60. LUSCHER TF
    An update on heart failure: from experimental findings to clinical trials.
    Eur Heart J. 2017;38:305-307.
    PubMed     Text format    
    
    
    
61. TOFIELD A
    Teenage weight and risk for adult heart failure.
    Eur Heart J. 2017;38:311-312.
    PubMed     Text format    
    
    
    
62. TOFIELD A
    End of the road for aliskiren in heart failure.
    Eur Heart J. 2017;38:312-313.
    PubMed     Text format    
    
    
    
63. 
    Professor Jay Cohn a pioneer in heart failure.
    Eur Heart J. 2017;38:308-309.
    PubMed     Text format    
    
    
    
64. HARPER AR, Cowie MR
    Remote monitoring for heart failure: the story moves on.
    Eur Heart J. 2017;38:310-311.
    PubMed     Text format    
    
    
    January 2017
65. BRUNO RM, Taddei S
    Sacubril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
    Eur Heart J. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format    
    
    
    
66. LANDIN AM, Hare JM
    The quest for a successful cell-based therapeutic approach for heart failure.
    Eur Heart J. 2017 Jan 10. pii: ehw626. doi: 10.1093.
    PubMed     Text format    
    
    
    
67. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
    Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
    Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
    PubMed     Text format    
    
    
    
68. CHATTERJEE NA, Borgquist R, Chang Y, Lewey J, et al
    Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.
    Eur Heart J. 2017 Jan 8. pii: ehw598. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
69. MAGGIONI AP, Ruschitzka F
    The year in cardiology 2016: heart failure.
    Eur Heart J. 2017 Jan 2. pii: ehw638. doi: 10.1093.
    PubMed     Text format    
    
    
    December 2016
70. MAISEL AS, Di Somma S
    Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).
    Eur Heart J. 2016 Dec 27. pii: ehw462. doi: 10.1093.
    PubMed     Text format    
    
    
    
71. NAKAMURA T, Masumoto A, Tahara N, Kuroda Y, et al
    Acute heart failure caused by mechanical valve leaflet dislodgment at the mitral position.
    Eur Heart J. 2016 Dec 23. pii: ehw521. doi: 10.1093.
    PubMed     Text format    
    
    
    
72. BARTUNEK J, Terzic A, Davison BA, Filippatos GS, et al
    Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
    Eur Heart J. 2016 Dec 23. pii: ehw543. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
73. HOEPER MM, Lam CS, Vachiery JL, Bauersachs J, et al
    Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchdagger.
    Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093.
    PubMed     Text format    
    
    
    
74. MINOIA C, Paolillo S
    Two weeks at Harvard, for two European heart failure trainees.
    Eur Heart J. 2016;37:3553-3554.
    PubMed     Text format    
    
    
    
75. PAOLILLO S
    The ESC Heart Failure Association postgraduate course in heart failure.
    Eur Heart J. 2016;37:3551-3552.
    PubMed     Text format    
    
    
    November 2016
76. AMMIRATI E, Burns JC, Moreo A, Daniels LB, et al
    Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
77. 
    What the Heart Failure Congress means to the Heart Failure Association.
    Eur Heart J. 2016;37:3124-3126.
    PubMed     Text format    
    
    
    
78. 
    First European advice launched for acute heart failure.
    Eur Heart J. 2016;37:3123-3124.
    PubMed     Text format    
    
    
    
79. 
    What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?
    Eur Heart J. 2016;37:3121-3122.
    PubMed     Text format    
    
    
    October 2016
80. CREA F, Bairey Merz CN, Beltrame JF, Kaski JC, et al
    The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
81. DOCHERTY KF, Campbell RT, Jhund PS, Petrie MC, et al
    How robust are clinical trials in heart failure?
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    September 2016
82. JORGE C, Hiltrop N, Desmet W
    Heart failure with preserved ejection fraction: blame the veins....
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
83. MOHSENI H, Kiran A, Khorshidi R, Rahimi K, et al
    Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    
84. JHUND PS
    Obesity and heart failure: when 'epidemics' collide.
    Eur Heart J. 2016 Sep 22. doi: 10.1093.
    PubMed     Text format    
    
    
    
85. FRADLEY MG
    The evolving field of cardio-oncology: beyond anthracyclines and heart failure.
    Eur Heart J. 2016;37:2740-2742.
    PubMed     Text format    
    
    
    
86. ZHABYEYEV P, Oudit GY
    Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
87. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
    Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
88. 
    The Acute Heart Failure Academy.
    Eur Heart J. 2016;37:2568-9.
    PubMed     Text format    
    
    
    
89. LUSCHER TF
    From heart failure to transplantation: genes, miRNAs, and biomarkers.
    Eur Heart J. 2016;37:2561-3.
    PubMed     Text format    
    
    
    August 2016
90. HADDAD S, Wang Y, Galy B, Korf-Klingebiel M, et al
    Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    
91. LAM CS, Teng TK, Tay WT, Anand I, et al
    Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    July 2016
92. ZANNAD F, Ferreira JP
    Globalization of heart failure trials: no turning back on this paradigm.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
93. LUSCHER TF
    Breaking news in heart failure: ESC Guidelines 2016, non-steroidal mineralocorticoid receptor antagonist, and alternate site CRT pacing.
    Eur Heart J. 2016;37:2085-7.
    PubMed     Text format    
    
    
    
94. HINDRICKS G, Varma N
    Remote monitoring and heart failure: monitoring parameters, technology, and workflow.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    June 2016
95. KRISTENSEN SL, Martinez F, Jhund PS, Arango JL, et al
    Geographic variations in the PARADIGM-HF heart failure trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    
96. VON ROEDER M, Rommel KP, Blazek S, Daehnert I, et al
    Pressure-volume-loop-guided closure of an iatrogenic atrial septal defect for right heart failure following MitraClip-implantation.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
97. EPSTEIN M, Pitt BC
    A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden frui
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
98. BORLAUG BA, Kane GC, Melenovsky V, Olson TP, et al
    Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    
99. ROSENGREN A, Aberg M, Robertson J, Waern M, et al
    Body weight in adolescence and long-term risk of early heart failure in adulthood among men in Sweden.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    
100. LUSCHER TF
     Frontiers in heart failure: assessement, risk factors, and novel genetic and cell-based therapies.
     Eur Heart J. 2016;37:1629-32.
     PubMed     Text format    
     
     
     
101. FERREIRA JP, Girerd N, Alshalash S, Konstam MA, et al
     Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     May 2016
102. PONIKOWSKI P, Voors AA, Anker SD, Bueno H, et al
     2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contributio
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
103. ANTMAN EM, Bax J, Chazal RA, Creager MA, et al
     Updated Clinical Practice Guidelines on Heart Failure: An International Alignment.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
104. LUSCHER TF
     Frontiers in congenital heart disease: pulmonary hypertension, heart failure, and arrhythmias.
     Eur Heart J. 2016;37:1407-9.
     PubMed     Text format    
     
     
     April 2016
105. NAEGELE M, Hernandez AF, Ruschitzka F
     Finerenone in heart failure: walking a fine line.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
106. FILIPPATOS G, Anker SD, Bohm M, Gheorghiade M, et al
     A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
107. ARAS MA, Teerlink JR
     Lung ultrasound: a 'B-line' to the prediction of decompensated heart failure.
     Eur Heart J. 2016;37:1252-4.
     PubMed     Text format    
     
     
     
108. LUSCHER TF
     Imaging as a basis of clinical decision-making in congenital and coronary disease and heart failure.
     Eur Heart J. 2016;37:1171-3.
     PubMed     Text format    
     
     
     
109. SMISETH OA, Torp H, Opdahl A, Haugaa KH, et al
     Myocardial strain imaging: how useful is it in clinical decision making?
     Eur Heart J. 2016;37:1196-207.
     PubMed     Text format     Abstract available
     
     
     
110. PATIL NP, Weymann A, Popov AF, Simon AR, et al
     Chest X-ray in cardiac illness: a tale of four decades.
     Eur Heart J. 2016;37:1243.
     PubMed     Text format    
     
     
     
111. DESAI AS, Jhund PS
     After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
112. BAHLS M, Felix SB
     Cachexia and right ventricular dysfunction in chronic heart failure: what is the chicken and what the egg?
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
113. SCHWARZL M, Ojeda F, Zeller T, Seiffert M, et al
     Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
114. MADONNA R, Van Laake LW, Davidson SM, Engel FB, et al
     Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
115. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
     Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
     Eur Heart J. 2016;37:1015-23.
     PubMed     Text format    
     
     
     March 2016
116. LUSCHER TF
     Update on hypertension: target blood pressure, comorbidities, and outcome.
     Eur Heart J. 2016;37:921-3.
     PubMed     Text format    
     
     
     
117. BOHM M, Drexler H, Oswald H, Rybak K, et al
     Fluid status telemedicine alerts for heart failure: a randomized controlled trial.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
118. AUER J, Wallner M, Windpessl M, Schmidt WM, et al
     Acute decompensated heart failure associated with a heteroplasmic 3243A>G mitochondrial DNA point mutation.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
119. BRAUNWALD E
     Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
     Eur Heart J. 2016;37:745-6.
     PubMed     Text format    
     
     
     February 2016
120. HULOT JS, Ishikawa K, Hajjar RJ
     Gene therapy for the treatment of heart failure: promise postponed.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
121. SWEDBERG K, Ryden L
     Treatment of diabetes and heart failure: joint forces.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
122. LOCH A, Geh DJ, Veriah RS
     Cardiac magnetic resonance imaging: a tool to diagnose parasitic infection?
     Eur Heart J. 2016;37:702.
     PubMed     Text format    
     
     
     
123. VALENTOVA M, von Haehling S, Bauditz J, Doehner W, et al
     Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
124. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
     Agents with vasodilator properties in acute heart failure.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
125. LUSCHER TF
     Heart failure and left ventricular remodelling in HFrEF and HFpEF.
     Eur Heart J. 2016;37:423-4.
     PubMed     Text format    
     
     
     
126. STROMBERG A, Wodlin P
     CardioPulse; Pocket-sized ultrasound for nurses in heart failure?
     Eur Heart J. 2016;37:434-5.
     PubMed     Text format    
     
     
     
127. TCHAMBAZ L
     CardioPulse: The second Postgraduate Course in Heart Failure: 2016-2017.
     Eur Heart J. 2016;37:430-1.
     PubMed     Text format    
     
     
     
128. BORLAUG BA
     Defining HFpEF: where do we draw the line?
     Eur Heart J. 2016;37:463-5.
     PubMed     Text format    
     
     
     
129. DWECK M, Chin C
     CardioPulse: Settling scores with a failing heart.
     Eur Heart J. 2016;37:433-4.
     PubMed     Text format    
     
     
     
130. WESTENBRINK BD, van Laake LW, Brugts JJ
     CardioPulse: The Postgraduate Course in Heart Failure.
     Eur Heart J. 2016;37:428-9.
     PubMed     Text format    
     
     
     
131. DIMARCO A, Mansoubi H, Tanner M
     An unusual cause of left ventricular hypertrophy.
     Eur Heart J. 2016;37:497.
     PubMed     Text format    
     
     
     
132. LECLERCQ C, Sadoul N, Mont L, Defaye P, et al
     Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.
     Eur Heart J. 2016;37:473-83.
     PubMed     Text format     Abstract available
     
     
     
133. STONE GW, Chung ES, Stancak B, Svendsen JH, et al
     Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.
     Eur Heart J. 2016;37:484-93.
     PubMed     Text format     Abstract available
     
     
     January 2016
134. FITCHETT D, Zinman B, Wanner C, Lachin JM, et al
     Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
135. PLATZ E, Lewis EF, Uno H, Peck J, et al
     Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patientsdagger.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
136. WANG K, Long B, Liu F, Wang JX, et al
     A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
137. RABER L, Piccolo R
     CardioPulse: Different bleeding scores and which one should we use?
     Eur Heart J. 2016;37:327-31.
     PubMed     Text format    
     
     
     
138. BUDTS W, Roos-Hesselink J, Radle-Hurst T, Eicken A, et al
     Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
139. NICHOLLS M
     CardioPulse: Cyclosporine to reduce myocardial infarction injury?
     Eur Heart J. 2016;37:210-1.
     PubMed     Text format    
     
     
     
140. KOMAJDA M, Ruschitzka F
     The year in cardiology 2015: heart failure.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     December 2015
141. IUNG B, Doco-Lecompte T, Chocron S, Strady C, et al
     Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
142. HIGASHI H, Inaba S, Izutani H, Sumimoto T, et al
     An unusual cause of life-threatening right-sided heart failure: undifferentiated pleomorphic sarcoma in the right ventricular outflow tract.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     November 2015
143. PULS M, Lubos E, Boekstegers P, von Bardeleben RS, et al
     One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
144. OLDENBURG O, Wellmann B, Buchholz A, Bitter T, et al
     Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
145. LUSCHER TF
     Infections, infarction, and heart failure: prevention and management.
     Eur Heart J. 2015;36:3033-5.
     PubMed     Text format    
     
     
     
146. MCMURRAY JJ
     Improving outcomes in heart failure: a personal perspectivedagger.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
147. SKOURI H, Dickstein K
     Heart failure in the Middle East An Emerging Challenge in a Diverse Environment.
     Eur Heart J. 2015;36:2970-2.
     PubMed     Text format    
     
     
     
148. VAN VELDHUISEN DJ, Ruilope LM, Maisel AS, Damman K, et al
     Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
149. WANG N, Hung CL, Shin SH, Claggett B, et al
     Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     October 2015
150. ROSENKRANZ S, Gibbs JS, Wachter R, De Marco T, et al
     Left ventricular heart failure and pulmonary hypertensiondagger.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
151. KATZ AM, Rolett EL
     Heart failure: when form fails to follow function.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     September 2015
152. KOTECHA D, Piccini JP
     Atrial fibrillation in heart failure: what should we do?
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
153. KASTRUP J
     Revival of cytokine therapy in heart failure?
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
154. CIKES M, Solomon SD
     Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
155. FRANCIS GS, Thenappan T
     Beta-blockers in heart failure: do we finally have the last word?
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
156. SOLOMON SD, Claggett B, Lewis EF, Desai A, et al
     Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
157. NICHOLLS M
     Research providing new insights into myocardial infarction injury.
     Eur Heart J. 2015;36:2345-6.
     PubMed     Text format    
     
     
     
158. LUSCHER TF
     Risk factors for and management of heart failure.
     Eur Heart J. 2015;36:2267-9.
     PubMed     Text format    
     
     
     August 2015
159. GORCSAN J 3RD, Sogaard P, Bax JJ, Singh JP, et al
     Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
160. MALASA M, Werner N, Nickenig G, Hammerstingl C, et al
     Transcatheter tricuspid valve repair in a patient with isolated functional tricuspid valve regurgitation.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
161. GORCSAN J 3RD, Schwartzman D
     Ventricular arrhythmias after cardiac resynchronization therapy: does reverse remodelling reverse risk?
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
162. LUSCHER TF
     Prevention of non-communicable diseases and special causes of heart failure.
     Eur Heart J. 2015;36:2019-2022.
     PubMed     Text format    
     
     
     
163. CHATTERJEE NA, Roka A, Lubitz SA, Gold MR, et al
     Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
164. LUSCHER TF
     Novel aspects of heart failure: from combined neurohormal blockade to embryonic stem cells.
     Eur Heart J. 2015;36:1937-9.
     PubMed     Text format    
     
     
     
165. TAYLOR J
     Depression associated with five-fold increased mortality risk in heart failure patients.
     Eur Heart J. 2015;36:1946.
     PubMed     Text format    
     
     
     
166. TAYLOR J
     Cognitive impairment predicts worse outcome in heart failure.
     Eur Heart J. 2015;36:1945.
     PubMed     Text format    
     
     
     
167. TOFIELD A
     Digoxin mortality in heart failure and atrial fibrillation.
     Eur Heart J. 2015;36:1944-5.
     PubMed     Text format    
     
     
     
168. PERRONE-FILARDI P, Paolillo S, Costanzo P, Savarese G, et al
     The role of metabolic syndrome in heart failure.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     July 2015
169. GONZALEZ-LOPEZ E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, et al
     Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
170. CASTANO A, Bokhari S, Maurer MS
     Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
171. CORRADO D, Wichter T, Link MS, Hauer R, et al
     Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
172. DICKSTEIN K
     Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
173. HOENDERMIS ES, Liu LC, Hummel YM, van der Meer P, et al
     Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
174. BORLAUG BA
     Taking aim at pulmonary hypertension in heart failure with preserved ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
175. STONE GW, Adams DH, Abraham WT, Kappetein AP, et al
     Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
176. GUO J, Mihic A, Wu J, Zhang Y, et al
     Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
177. MUNZEL T, Gori T, Keaney JF Jr, Maack C, et al
     Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     June 2015
178. FADINI GP, Avogaro A, Degli Esposti L, Russo P, et al
     Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
179. TOFIELD A
     Blood sugar levels in heart failure patients predict risk of early death, hospitalizations, and diabetes.
     Eur Heart J. 2015;36:1498-9.
     PubMed     Text format    
     
     
     
180. GIRERD N, Collier T, Pocock S, Krum H, et al
     Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
181. FELKER GM
     Augmenting outcomes in patients with advanced heart failure.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
182. YSSAP J, Lebreton G, Hoen B, Larifla L, et al
     Infected left ventricular thrombus revealing an unrecognized coronary dissection after blunt chest trauma, treated with emergency heart transplantation.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
183. PARKER JD
     Therapeutic developments in the therapy of heart failure: lessons to be learned.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
184. ANKER SD, Coats AJ, Cristian G, Dragomir D, et al
     A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
185. FANKHAUSER CD, Nietlispach F, Emmert MY, Maisano F, et al
     Antegrade valve embolization after transcatheter treatment for pure aortic regurgitation.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
186. LUSCHER TF
     Heart failure and comorbidities: renal failure, diabetes, atrial fibrillation, and inflammation.
     Eur Heart J. 2015;36:1415-7.
     PubMed     Text format    
     
     
     
187. EDNER M, Benson L, Dahlstrom U, Lund LH, et al
     Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
188. CHUNG ES, Miller L, Patel AN, Anderson RD, et al
     Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
189. AMSTEIN R, Luscher TF, Maisano F, Ruschitzka FT, et al
     The new postgraduate course in heart failure (PCHF): update on 1st PCHF and announcement of the 2nd PCHF. A project of the European Society of Cardiology Heart Failure Association, the ESC European Heart Academy, the Zurich Heart House and the Univers
     Eur Heart J. 2015;36:1354-5.
     PubMed     Text format    
     
     
     May 2015
190. DESAI AS, McMurray JJ, Packer M, Swedberg K, et al
     Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
191. MEBAZAA A, Yilmaz MB, Levy P, Ponikowski P, et al
     Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Em
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
192. MENASCHE P, Vanneaux V, Hagege A, Bel A, et al
     Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
193. FLORAS JS, Ponikowski P
     The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
194. SLIWA K, Johnson MR, Zilla P, Roos-Hesselink JW, et al
     Management of valvular disease in pregnancy: a global perspective.
     Eur Heart J. 2015;36:1078-89.
     PubMed     Text format     Abstract available
     
     
     
195. HILFIKER-KLEINER D, Haghikia A, Nonhoff J, Bauersachs J, et al
     Peripartum cardiomyopathy: current management and future perspectives.
     Eur Heart J. 2015;36:1090-7.
     PubMed     Text format     Abstract available
     
     
     
196. BUCKLEY U, Shivkumar K
     Implantable cardioverter defibrillators: even better than we thought?
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     April 2015
197. RAPHAEL CE, Finegold JA, Barron AJ, Whinnett ZI, et al
     The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
198. SOLOMON S, Goncalves A
     CardioPulse: drinking moderate amounts of alcohol is linked to reduced risk of heart failure.
     Eur Heart J. 2015;36:890-1.
     PubMed     Text format    
     
     
     
199. CONEN D
     Alcohol consumption and incident cardiovascular disease: not just one unifying hypothesis.
     Eur Heart J. 2015;36:897-8.
     PubMed     Text format    
     
     
     
200. 
     Stem cells for heart failure: the experience of writing a Cochrane systematic review.
     Eur Heart J. 2015;36:834-6.
     PubMed     Text format    
     
     
     
201. HILFIKER-KLEINER D, Westhoff-Bleck M, Gunter HH, von Kaisenberg CS, et al
     A management algorithm for acute heart failure in pregnancy. The Hannover experience.
     Eur Heart J. 2015;36:769-70.
     PubMed     Text format    
     
     
     March 2015
202. AMINZADEH MA, Tseliou E, Sun B, Cheng K, et al
     Therapeutic efficacy of cardiosphere-derived cells in a transgenic mouse model of non-ischaemic dilated cardiomyopathy.
     Eur Heart J. 2015;36:751-62.
     PubMed     Text format     Abstract available
     
     
     
203. SAVVATIS K, Schultheiss HP, Tschope C
     Endomyocardial biopsy and ultrastructural changes in dilated cardiomyopathy: taking a 'deeper' look into patients' prognosis.
     Eur Heart J. 2015;36:708-10.
     PubMed     Text format    
     
     
     
204. NABETA T, Itatani K, Miyaji K, Ako J, et al
     Vortex flow energy loss reflects therapeutic effect in dilated cardiomyopathy.
     Eur Heart J. 2015;36:637.
     PubMed     Text format    
     
     
     February 2015
205. CALIFF RM
     LCZ696: too good to be true?
     Eur Heart J. 2015;36:410-2.
     PubMed     Text format    
     
     
     
206. LUBITZ SA, Singh JP
     Biventricular pacing: more is better!
     Eur Heart J. 2015;36:407-9.
     PubMed     Text format    
     
     
     January 2015
207. BANYPERSAD SM, Fontana M, Maestrini V, Sado DM, et al
     T1 mapping and survival in systemic light-chain amyloidosis.
     Eur Heart J. 2015;36:244-51.
     PubMed     Text format     Abstract available
     
     
     September 2014
208. MIZIA-STEC K, Wybraniec MT, Bochenek T, Gierlaszynska K, et al
     Fulminant variant of Loeffler disease mimicking arrhythmogenic right ventricular cardiomyopathy in the course of enterobiasis.
     Eur Heart J. 2014.
     PubMed     Text format    
     
     
     
209. CLAEYS MJ
     High-sensitivity troponin: does it predict the shape of the iceberg underneath the surface?
     Eur Heart J. 2014;35:2273-5.
     PubMed     Text format    
     
     
     
210. KAYE GC, Linker NJ, Marwick TH, Pollock L, et al
     Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study.
     Eur Heart J. 2014.
     PubMed     Text format     Abstract available
     
     
     August 2014
211. FERRARI R, Rizzo P
     The Notch pathway: a novel target for myocardial remodelling therapy?
     Eur Heart J. 2014;35:2140-5.
     PubMed     Text format     Abstract available
     
     
     
212. NENSA F, Poeppel TD, Krings P, Schlosser T, et al
     Multiparametric assessment of myocarditis using simultaneous positron emission tomography/magnetic resonance imaging.
     Eur Heart J. 2014;35:2173.
     PubMed     Text format    
     
     
     
213. RUWALD AC, Kutyifa V, Ruwald MH, Solomon S, et al
     The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling.
     Eur Heart J. 2014.
     PubMed     Text format     Abstract available
     
     
     May 2014
214. CHIN CW, Shah AS, McAllister DA, Joanna Cowell S, et al
     High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis.
     Eur Heart J. 2014.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: